CLBIO: Corline Biomedical AB - Summary | Jitta

Corline Biomedical AB

SWE:CLBIO

Price
kr17.50
Loss Chance
57.9%
1.77JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
27 / 105
261 / 618
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (29)
Recent Business Performance (19)
Financial Strength (44)
Return to Shareholders (0)
Competitive Advantage (21)
Jitta Signs
Cash Conversion CycleLess than 30 days
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 6.57% in the last year
SG&A to SalesIncreasing
Key Stats
Jitta Score
Jitta Line
1.77
100.00%
2.03
105.70%
2.89
158.61%
Pharmaceuticals
6.20
209.44%
2.06
100.00%
2.86
100.00%
COMPANY DESCRIPTION
Corline Biomedical AB develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications in Sweden. The company’s products are based on Corline Heparin Conjugate (CHC) technology, a naturally occurring biomolecule heaparin, which is routinely used in surgery as an anticoagulant pharmaceutical compound to prevent harmful blood clotting. It offers CHS stent, a metallic tube-shaped device for the treatment of acute or threatened vessel closure during coronary angioplasty; CHS Coated Ablation Catheter to treat heart arrythmia; Renaparin for use in the treatment of end stage renal failure; and CHC, which is used for the treatment of soft tissue injuries. Corline Biomedical AB was incorporated in 1991 and is based in Uppsala, Sweden.